Journal of Arthritis and RheumatologyJournal of Arthritis and RheumatologyJournal of Arthritis and RheumatologyA randomized, double-blind, placebo controlled, period III clinical demo evaluated the efficacy and protection profile of adalimumab as being a monotherapy in patients with RA who had failed to reply to csDMARDs [191]. The results showed e